baber/WOPTO huggingface dataset:
Patent NZ-595891-A (NZ)
Title: Modulation of inflammatory responses by factor xi
Inventor: MONIA BRETT P
IPC: A61K48/00
Filed: 2010-04-15
Abstract: 595891 MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI Provided is the use of a Factor XI modulator compound in the manufacture of a medicament for modulating an inflammatory response in an animal. The modulator can be a modified oligonucleotide targeting Factor XI, a peptide, antibody or small molecule. Specific antisense oligos suitable for the purpose are also disclosed.
Patent NZ-595914-A (NZ)
Title: Vaccines comprising attenuated mycoplasma bovis strains and method for the attenuation
Inventor: BECK MICHAEL
IPC: A61K39/02
Filed: 2010-04-23
Abstract: An immunogenic composition comprising an attenuated, avirulent Mycoplasma bovis bacterium strain wherein the bacterium is passaged more than 110 times, wherein the attenuated, avirulent Mycoplasma bovis strain is selected from the group consisting of: The attenuated M.bovis strain deposited with the ATCC under accession number PTA-9666 or M.bovis strain with the same characteristics or The attenuated M.bovis strain deposited with the ATCC under accession number PTA-9667 or M.bovis strain with the same characteristics or any attenuated, avirulent Mycoplasma bovis bacterium strain having the characteristic that its administration to a group of non-human animals in the form of a live vaccine reduces the mortality and euthanization rate in the group of animals by at least 56% as compared to a non-vaccinated control group of animals after the administration of a single dose of said vaccine.
Patent NZ-595929-A (NZ)
Title: Mobile phone application which recognises text on product or store and overlays relevant information on video display
Inventor: WAN JAMES YOONG-SIANG
IPC: H04M11/08
Filed: 2011-10-25
Abstract: Disclosed is a platform for recognising text using mobile devices (20) with built-in video cameras (21). The platform includes a database (35) for storing machine-encoded text and associated content corresponding to the machine-encoded text, a text-detection engine (32) and an executable mobile application (30). The text detection engine (32) detects the presence of text in a live video feed captured by the built-in device video camera (21) in real time and converts the detected text into machine-encoded text in real time. The mobile application (30) includes a display module (31) for displaying the live video feed on a screen (24) of the mobile device (20) and a content retrieval module (34) for retrieving the associated content by querying the database (35) based on the machine-encoded text converted by the text-detection engine (32). The retrieved associated content is superimposed in the form of Augmented Reality (AR) content on the live video feed in real time. The AR content has user selectable graphical user interface components that, when selected by a user, retrieve digital content remotely stored from the mobile device (20). The detection and conversion of text and superimposition of AR content are performed without user input to the mobile application (30).
Patent NZ-603200-A (NZ)
Title: Peptides and their use
Inventor: O’NEIL DEBORAH
IPC: A61K9/08
Filed: 2011-03-30
Abstract: 603200 Discloses a peptide consisting of the amino acid sequence RRRFRFFFRFRRR with zero, one or two amino acids and the use of the peptide in the manufacture of a medicament for the treatment or alleviation of a microbial infection or condition.
Patent NZ-603211-A (NZ)
Title: Expandable and contractible hose
Inventor: BERARDI MICHAEL
IPC: F16L11/12
Filed: 2012-04-03
Abstract: 603211 A hose (10) which automatically extends longitudinally and expands laterally upon the application of a fluid pressure is disclosed. The hose can automatically extend longitudinally up to six times its unexpanded or contracted length in an extended condition. Upon release of the fluid pressure within the hose, the hose will automatically contract to a contracted condition. The hose includes an inner tube (14) made from an elastic material and an outer tube (12) made from a nonelastic material. The inner tube is positioned concentrically within the outer tube. The outer tube is secured to the inner tube only at a first end of the inner and outer tubes and at a second end of the inner and outer tubes. A first coupler (18) is secured to a first end of the inner and outer tubes. A second coupler (16) is secured to a second end of the inner and outer tubes. The first coupler may be a female coupler and the second coupler may be a male coupler. The second coupler couples the hose to a water flow restrictor, such as a nozzle or sprayer, which allows water under pressure to discharge while also providing a fluid back pressure within the hose. In the extended condition the inner tube is stretched such that the wall thickness of the inner tube is decreased.
Patent NZ-611820-A (NZ)
Title: Monomeric and multimeric immunogenic peptides
Inventor: GRØNVOLD MAJA SOMMERFELT
IPC: A61K39/12
Filed: 2012-01-06
Abstract: Disclosed is an isolated multimeric peptide comprising two or more monomeric peptides, each monomeric peptide independently consisting of not more than 60 amino acids with the following structure: X1-X2-X3-X4-X5-X6 (formula I), wherein: X1, X3 and optional moiety X5 each independently define a linear sequence of any 1, 2, 3, 4, or 5 amino acids independently selected from glycine, arginine, norleucine, aspartic acid, glutamic acid, glutamine, serine, lysine, tryptophan, cysteine, ornithine, diaminopropionic acid or a derivative thereof; X2, X4 and optional moiety X6 each independently define a linear sequence of 5-17 amino acids, each having 50% or more sequence identity to a specific natural antigen; the monomeric peptides being covalently joined by one or more intermolecular bonds; wherein in one of the monomeric peptides the sequence of X2 is selected from IEEEG (SEQ ID NO: 72) and GIEEE (SEQ ID NO: 76), X3 is G or GG, and X4 is RDRDR (SEQ ID NO: 95), with the proviso that this peptide is not GKGGIEEEGGRDRDRGGEQDRDR (SEQ ID NO: 122). Also disclosed is a method for evaluating the efficacy of a vaccine comprising stimulating a sample of peripheral blood mononuclear cells (PBMCs) obtained from a patient treated with the vaccine with the multimeric peptide as defined above.
Patent NZ-618068-A (NZ)
Title: Method for controlling a pump
Inventor: LARSSON MARTIN
IPC: G05B13/02
Filed: 2012-05-31
Abstract: The invention relates to a method for automatic mutual alternation between an arbitrary number of pumps by the control of an individual pump, which makes use of a start condition for a state change from an inactive state of the pump into an active state of the pump to be performed, as well as makes use of a stop condition for a state change from said active state into said inactive state to be performed. According to the invention, the method comprises a sub method (Find start condition) that comprises the step of, after a predetermined stage, arbitrarily changing the start condition of the individual pump within predetermined limits. The step of arbitrarily changing the start condition of the pump comprises the step of determining a pump start liquid level.
Patent NZ-622860-A (NZ)
Title: Use of non-subtype b gag proteins for lentiviral packaging
Inventor: TRAN THI-LAN
IPC: C12N15/867
Filed: 2012-09-25
Abstract: Disclosed is a replication-defective lentiviral packaging vector lacking a Ψ site and encoding a subtype D HIV-1 Gag-Pol protein.
Patent NZ-623341-A (NZ)
Title: Compounds for improved viral transduction
Inventor: HEFFNER GARRETT COLLINS
IPC: C12N15/86
Filed: 2012-09-28
Abstract: A method for increasing the transduction efficiency of cells cultured with a retrovirus comprising: culturing the cells and the retrovirus in a culture medium that comprises a compound that increases prostaglandin EP receptor signalling is disclosed. The cells are cultured with the retrovirus during, or prior to, culture with the compound that increases prostaglandin EP receptor signaling, and the compound that increases prostaglandin EP receptor signaling is selected from the group consisting of: PGA2; PGB2; PGD2; PGE1; PGE2; PGF2; PGI2; PGH2; PGJ2; and precursors, metabolites, derivatives and analogues thereof, or the compound that increases prostaglandin EP receptor signaling is selected from the group consisting of: 15d-PGJ2; delta12-PGJ2; 2-hydroxyheptadecatrienoic acid (HHT); Thromboxane A2; Thromboxane B2; Iloprost; Treprostinil; Travoprost; Carboprost tromethamine; Tafluprost; Latanoprost; Bimatoprost; Unoprostone isopropyl; Cloprostenol; Oestrophan; Superphan; Misoprostol; Butaprost; Linoleic Acid; 13(s)-HODE; LY171883; Mead Acid; Eicosatrienoic Acid; Epoxyeicosatrienoic Acid; ONO-259; Cay1039; a PGE2 receptor agonist; 16,16-dimethyl PGE2; 19(R)-hydroxy PGE2; 16,16-dimethyl PGE2 p-(p-acetamidobenzamido) phenyl ester; 11-deoxy-16,16-dimethyl PGE2; 9-deoxy-9-methylene-16,16-dimethyl PGE2; 9-deoxy-9-methylene PGE2; Sulprostone; PGE2serinol amide; PGE2 methyl ester; 16-phenyl tetranor PGE2; 15(S)-15-methyl PGE2; 15(R)-15-methyl PGE2; BIO; 8-bromo-cAMP; Forskolin; Bapta-AM; Fendiline; Nicardipine; Nifedipine; Pimozide; Strophanthidin; Lanatoside; L-Arg; Sodium Nitroprusside; Sodium Vanadate; Bradykinin; Mebeverine; Flurandrenolide; Atenolol; Pindolol; Gaboxadol; Kynurenic Acid; Hydralazine; Thiabendazole; Bicuclline; Vesamicol; Peruvoside; Imipramine; Chlorpropamide; 1,5-Pentamethylenetetrazole; 4-Aminopyridine; Diazoxide; Benfotiamine; 12-Methoxydodecenoic acid; N-Formyl-Met-Leu-Phe; Gallamine; IAA 94; and Chlorotrianisene, or the compound that increases prostaglandin EP receptor signaling is selected from the group consisting of: prostaglandin E2(PGE2), or 16,16-dimethyl PGE2. The cells can be stem or progenitor cells such as embryonic stem cells and induced pluripotent stem cells.
Patent NZ-627896-A (NZ)
Title: Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
Inventor: DE VISSER PETER CHRISTIAN
IPC: A61P21/00
Filed: 2013-01-28
Abstract: Discloses an oligonucleotide comprising a 2’ -O-methyl RNA monomer and a phosphorothioate backbone and comprising a 5-methyluracil and/or a 5-methylcytosine and/or a 2,6-diaminopurine base for use in the treatment of Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.
Patent NZ-630489-A (NZ)
Title: Bicyclic pyrazinone derivatives
Inventor: Moinet Gérard
IPC: C07D487/04
Filed: 2013-03-19
Abstract: Disclosed herein are pyrrolo-pyrazinone or pyrazolo-pyrazinone compounds of the formula (I), where the substituents are as defined herein. The compounds are inhibitors of Tankyrase, and can be employed for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. Specific examples of the compounds of formula I include 7-fluoro-3-[4-(1-hydroxy-cyclopentyl)-phenyl]-2H-pyrrolo[1,2-a]pyrazin-1-one and 6-(4-tert-butyl-phenyl)-5H-pyrazolo[1,5-a]pyrazin-4-one.
Patent NZ-704180-A (NZ)
Title: Improved method for preparing shut down of process and equipment for producing liquid hydrocarbons
Inventor: IVERSEN STEEN BRUMMERSTEDT
IPC: C10G3/00
Filed: 2013-08-29
Abstract: The invention relates to a continous process for converting carbonaceous material contained in one or more feedstocks into a liquid hydrocarbon product, said feedstocks including the carbonaceous material being in a feed mixture including one or more fluids, said fluids including water, the process comprising : converting at least part of the carbonaceous material by: pressurising the feed mixture to an operational pressure in the range 150- 400 bar, heating the feed mixture to an operational temperature in the range 300-450 °C, and maintaining said pressurized and heated feed mixture in the desired pressure and temperature ranges in a reaction zone for a predefined time; cooling the feed mixture to a temperature in the range 25-200 °C and expanding the feed mixture to a pressure in the range of 1-70 bar, thereby causing the carbonaceous material to be converted to a liquid hydrocarbon product; and separating from the converted feed mixture a fraction comprising liquid hydrocarbon product; where in a state of discontinued operation the inflow of feed mixture is terminated and the system is filled with a fluid;where the pressure and temperature is set to a predetermined desired level, where the temperature and the pressure are altered to the predetermined lower level at a predetermined rate and where the pressure during the altering is constantly kept at a level above the saturation pressure for the fluid at a given temparature.
Patent NZ-717130-A (NZ)
Title: Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
Inventor: MACDONALD LYNN
IPC: C07K14/705
Filed: 2012-10-26
Abstract: Discloses an isolated non-human animal cell comprising at an endogenous Major Histocompatibility Complex II (MHC II) α gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II α polypeptide, wherein a human portion of the chimeric human/non-human MHC II α polypeptide comprises a human MHC II α2 domain. Also disclosed is an isolated non-human animal cell comprising at an endogenous MHC II β gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II β polypeptide, wherein a human portion of the chimeric human/non-human MHC II β polypeptide comprises a human MHC II β2 domain.
Patent NZ-721260-A (NZ)
Title: Antenna coupling for sensing and dynamic transmission
Inventor: MERCER SEAN RUSSELL
IPC: H04W52/24
Filed: 2014-12-26
Abstract: A wireless transmission system disclosed herein includes a transmitter-receiver pair. When a dielectric object approaches the transmitter-receiver pair, a signal strength of a transmitted carrier wave increases at the receiver. In response, transmission power of the transmitter can be dynamically reduced. When the dielectric object moves away from the transmitter-receiver pair, a signal strength of the carrier wave decreases at the receiver. In response, the transmission power of the transmitter can be dynamically increased.
Patent NZ-730788-A (NZ)
Title: Method and system for making customized formulations for individuals
Inventor: NOEL LLOYD
IPC: G16H20/60
Filed: 2014-03-12
Abstract: There is a need for customized formulations of dietary supplements and therapeutics based on the genetic, physical, physiological, and medical needs of an individual. Conventionally, typical formulations of supplements and therapeutics are prepared as a pill or liquid in batches comprised of a fixed set of ingredients to be used by the average person with little regard to the needs of that specific individual. Diagnostic advances in individual genomic sequencing and molecular diagnostics, for example, result in a need for corresponding innovation in the formulation and packaging of a range of compounds and biologics in a small batch production that is economic for individual consumption that addresses respective ailments. Further, there is recognized need to encourage greater consumer compliance in daily intake of key nutritional and pharmacological components in order to obtain desired outcomes, and a solution that uses natural human drives, such as taste and pleasure, if combined to suit individual subjective preferences will likely improve voluntary compliance with prescriptive nutrition and medicine. The embodiments disclosed herein provide a system and method for automatically assembling multiple compounds into a single edible custom composition, in which each compound is individually customized to proportions formulated from a profile of an individual or group. The system and method involves receiving health-related information for an individual from the individual, their agent, or a service provider, the health-related information including one of genetics or metabolomic profile data of the individual. Taste-related preference data is then received from the individual. Based on the health-related information, the present invention determines a formulation for an ingredient for the individual, and based on the taste-related preference data, determines a filler medium that is consistent with the taste-related preference data, wherein the filler medium is a thixotropic semi-solid hydrocolloid that allows dissolution or suspension of compounds in a form that is stable until agitated or extruded at which point the semi-solid hydrocolloid becomes fluid and can be dispensed. A preparation apparatus is involved that includes a formulation device configured to prepare the formulation, as well as a medium formulation device configured to prepare the filler medium. A dispenser is configured to dispense a predetermined amount of the formulation within the filler medium to form a dosage, wherein the thixotropic semi-solid hydrocolloid is solubilized to embed the formulation and then reformed as a semi-solid. The dosage is packaged as an individual use dosage in a packaging material.
Patent NZ-745817-A (NZ)
Title: Portable roller device
Inventor: JORGENSON SAMUEL C
IPC: A63B21/00
Filed: 2017-02-27
Abstract: A roller device includes a plurality of segments, wherein the plurality of segments is configured to form a tubular shape. In addition, each of the plurality of segments are coupled to neighboring segments of the plurality of segments and each of the plurality of segments include a first edge and a second edge, wherein the first edge is opposite the second edge. The roller device also includes a coupling mechanism for coupling the first edge of a segment to a second edge of a first neighboring segment and coupling the second edge of the segment to a first edge of a second neighboring segment, wherein the coupling mechanism allows the plurality of segments to convert from a first position to a second position. The segmented configuration allows for the device to be collapsed so storage space is saved when it is stowed and/or transported.
Patent NZ-747659-A (NZ)
Title: Improvements in and relating to animal effluent treatment system
Inventor: HONG JIE DI
IPC: C02F103/20
Filed: 2018-10-24
Abstract: A farm liquid animal effluent treatment system which includes: a catchment area which initially collects the animal effluent which is washed from an animal holding area; a containment area into which liquid animal effluent is fed from the catchment area via a conduit (with or without a pump); a single source of treatment agent in the form of coagulant which is connected to the conduit; wherein the source of coagulant is coupled to the conduit so as to deliver a predetermined amount of coagulant to the conduit via an injection port; and wherein the conduit is adapted to provide mixing of the coagulant and liquid animal effluent, at a point downstream of the injection port, so as to enable the coagulant to treat, or at least partially pre-treat, the liquid animal effluent before being delivered to the containment area by the conduit; wherein final coagulation and flocculation of solid and colloidal material occurs in the containment area resulting in the formation of a clarified liquid in the upper portion of the treated liquid animal effluent. The animal effluent treatment system can be retrofitted into existing effluent capture/treatment systems, has a relatively low equipment and installation cost, and can treat large volumes of effluent in a continuous manner.
Patent PT-116480-A (PT)
Title: Capacete de proteção viral ventilado reutilizável
Inventor: ANTÓNIO FRANCISCO FEBRA
IPC: A42B3/28
Filed: 2020-06-05
Abstract: A PRESENTE INVENÇÃO REFERE-SE A UM CAPACETE DE PROTEÇÃO VIRAL VENTILADO REUTILIZÁVEL VISANDO PROPORCIONAR AO MESMO TEMPO A PROTEÇÃO VIRAL AO UTILIZADOR, O CONFORTO RESPIRATÓRIO ATRAVÉS DA CIRCULAÇÃO DE AR NO INTERIOR DO CAPACETE E SEM PERDAS DO ÂNGULO DE VISÃO HUMANA E DE MOVIMENTOS. O CONJUNTO PODERÁ SER UTILIZADO POR QUALQUER AGENTE DE SAÚDE OU PÚBLICO, PROPORCIONANDO AO UTILIZADOR UM BOM CONFORTO E A POSSIBILIDADE DE EXERCER QUALQUER ATIVIDADE NAS DEVIDAS CONDIÇÕES. O CONJUNTO É CONSTITUÍDO PELA ESTRUTURA DO CAPACETE COM ABERTURA AO CENTRO (1), CONJUNTO DE BORRACHAS DE PROTEÇÃO (2), BORRACHA DE VEDAÇÃO (3), CONJUNTO DE VENTILAÇÃO (4) QUE PROVOCA A CIRCULAÇÃO DE AR NO INTERIOR DO CAPACETE, UM TRINCO DE ABERTURA/FECHO DO CAPACETE (5). OS MATERIAIS USADOS NO FABRICO DO CAPACETE PERMITEM A SUA LAVAGEM E DESINFEÇÃO E ASSIM A SUA REUTILIZAÇÃO.
Patent RU-94001142-A (RU)
Inventor: IVANOVSKIJ A P
IPC: B03D1/01
Filed: 1994-01-13
Abstract: FIELD: mining; floatation of copper and polymetal ores. SUBSTANCE: collecting and foaming agent contains 10-50% of bottom residue from 2-methyl-5-ethylpyridine rectification, 2-25% of the same from 2-methyl-2-vinylpyridine rectification, and 10-85% of waste water from 2-methyl-5- ethylpyridine production, bottom residues chiefly consisting of non-polymerized pyridine bases. EFFECT: increased floatation activity due to enhanced collecting and foaming properties and enlarged application possibilities.
Patent RU-94004198-A (RU)
Inventor: SKRIPNIK JU A
IPC: G01R19/00
Filed: 1994-02-08
Abstract: FIELD: instruments. SUBSTANCE: method involves three additional measuring conversions in neighborhood of working point of non-linear conversion function provided by measured value. First additional measurement is done for measured value that is increased by verification increment, second additional measurement is done for measured value that is increased after its division by constant factor, third additional measurement is done for measured value that is divided by same constant factor. Increments for additional measurements is minimal value that is multiple to sensitivity threshold of measuring converter. Then, level of non-linearity of response from measured value is determined by form of functional dependence. Corrected result of measurements is calculated after all measurements and it is multiplied by correction factor which depends on level of non- linearity of converter. EFFECT: increased precision of measurements having high level of non-linearity.
Patent RU-94004281-A (RU)
Inventor: ZINOV EV V V
IPC: A61Q19/00
Filed: 1994-02-03
Abstract: FIELD: cosmetic industry. SUBSTANCE: agent has gel, enzyme preparation and bioactive additions. Polyethylene oxide is used as gel and collase - as enzyme preparation. Bioactive additions - sea buckthorn or fir oil and propolis extract were taken at the following ratio of components, wt.-%: enzyme preparation collase 0.001-0.05; sea buckthorn or fir oil 0.2-5.0; propolis extract 0.1-10.0, and polyethylene oxide gel - the rest. Proposed agent does not contain elastase that can exhibit toxic and allergic action on the human organism. EFFECT: enhanced quality of agent proposed.
Patent RU-94018580-A (RU)
Title: Method of salts crushing
Inventor: IGNATOV E A
IPC: B02C19/16
Filed: 1994-05-23
Abstract: FIELD: processes for technological preparation of production processes in mechanical engineering, medicine and other fields. SUBSTANCE: method includes impating of vibration to the tool and supplying some substance relative to the surface of crystal. Method is distinguished by that effected first is operation for detection of resonance frequencies causing longitudinal, bending and shearing load accelerations, and, then, the object to be crushed is exposed to the effect of fixed frequencies of harmonics relative to the vibrator natural frequency according to the relations given in the invention description. EFFECT: higher productivity in salt crushing. 1 dwg